Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 423

1.

The role of FOXP3 in the development and metastatic spread of breast cancer.

Douglass S, Ali S, Meeson AP, Browell D, Kirby JA.

Cancer Metastasis Rev. 2012 Dec;31(3-4):843-54. doi: 10.1007/s10555-012-9395-3. Review. Erratum in: Cancer Metastasis Rev. 2013 Dec;32(3-4):763.

PMID:
22833279
2.

The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.

Fokas E, McKenna WG, Muschel RJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):823-42. doi: 10.1007/s10555-012-9394-4. Review.

PMID:
22825313
3.

Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.

Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A, Pérez Valderrama B, Viciana R.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S19-27. doi: 10.1007/s10555-012-9355-y. Review.

PMID:
22821550
4.

The optimize project: beyond first-line therapy in metastatic renal cell carcinoma.

Castellano D, Bellmunt J.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S1-2. doi: 10.1007/s10555-012-9393-5. No abstract available.

PMID:
22767406
5.

Metastatic view of breast cancer.

Banfalvi G.

Cancer Metastasis Rev. 2012 Dec;31(3-4):815-22. doi: 10.1007/s10555-012-9392-6. Review.

PMID:
22767405
6.

Cancer stem cells, microRNAs, and therapeutic strategies including natural products.

Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES.

Cancer Metastasis Rev. 2012 Dec;31(3-4):733-51. doi: 10.1007/s10555-012-9382-8. Review.

PMID:
22752409
7.

Maspin: molecular mechanisms and therapeutic implications.

Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, Hendrix MJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):529-51. doi: 10.1007/s10555-012-9361-0. Review.

PMID:
22752408
8.

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Suda K, Mizuuchi H, Maehara Y, Mitsudomi T.

Cancer Metastasis Rev. 2012 Dec;31(3-4):807-14. doi: 10.1007/s10555-012-9391-7. Review.

PMID:
22736441
9.

Transcription factor PROX1: its role in development and cancer.

Elsir T, Smits A, Lindström MS, Nistér M.

Cancer Metastasis Rev. 2012 Dec;31(3-4):793-805. doi: 10.1007/s10555-012-9390-8. Review.

PMID:
22733308
10.

The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis.

Meng F, Wu G.

Cancer Metastasis Rev. 2012 Dec;31(3-4):455-67. doi: 10.1007/s10555-012-9379-3. Review.

PMID:
22733307
11.

Plasticity of disseminating cancer cells in patients with epithelial malignancies.

Bednarz-Knoll N, Alix-Panabières C, Pantel K.

Cancer Metastasis Rev. 2012 Dec;31(3-4):673-87. doi: 10.1007/s10555-012-9370-z. Review.

PMID:
22733306
12.

Ovarian cancer molecular pathology.

Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, Day R, Fournier I, Salzet M.

Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32. doi: 10.1007/s10555-012-9383-7. Review.

13.

Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer.

Gunasinghe NP, Wells A, Thompson EW, Hugo HJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):469-78. doi: 10.1007/s10555-012-9377-5. Review.

PMID:
22729277
14.

The role of pharmacogenomics in metastatic renal cell carcinoma.

Castellano D, Virizuela JA, Cruz J, Sepulveda JM, Sáez MI, Paz-Ares L.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S29-32. doi: 10.1007/s10555-012-9356-x. Review. Erratum in: Cancer Metastasis Rev. 2013 Jun;32(1-2):317. Sáenz, Maribel [corrected to Sáez, María Isabel].

PMID:
22723081
15.

Role of the EpCAM (CD326) in prostate cancer metastasis and progression.

Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y.

Cancer Metastasis Rev. 2012 Dec;31(3-4):779-91. doi: 10.1007/s10555-012-9389-1. Review.

PMID:
22718399
16.

The faces and friends of RhoGDI2.

Griner EM, Theodorescu D.

Cancer Metastasis Rev. 2012 Dec;31(3-4):519-28. doi: 10.1007/s10555-012-9376-6. Review.

PMID:
22718398
17.

TGF-β signalling and its role in cancer progression and metastasis.

Drabsch Y, ten Dijke P.

Cancer Metastasis Rev. 2012 Dec;31(3-4):553-68. doi: 10.1007/s10555-012-9375-7. Review.

PMID:
22714591
18.

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.

Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, Danesi R.

Cancer Metastasis Rev. 2012 Dec;31(3-4):753-61. doi: 10.1007/s10555-012-9387-3. Review.

PMID:
22711031
19.

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment.

Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S, Blanchard H, Ralph SJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):763-78. doi: 10.1007/s10555-012-9388-2. Review.

PMID:
22706847
20.

Non-glucose metabolism in cancer cells--is it all in the fat?

Biswas S, Lunec J, Bartlett K.

Cancer Metastasis Rev. 2012 Dec;31(3-4):689-98. doi: 10.1007/s10555-012-9384-6. Review.

PMID:
22706846

Supplemental Content

Loading ...
Support Center